Morphochemical evaluation of neurotransplantation outcomes in experimental Parkinsonism

Abstract

Parkinson’s disease is characterized by degeneration of the nigrostriatal dopaminergic pathway that underlies the basic motor symptoms of the disease. Since the currently available antiparkinsonian therapy is symptomatic by its nature, approaches associated with intracerebral transplantation of functionally intact dopaminergic neurons derived from fibroblasts through the stage of induced pluripotent stem cells (iPSCs) are considered as an alternative. In this work, based on a model of 6-OHDA-induced Parkinsonism in rats, we have studied the long-term motor effects and provided morphochemical evaluation of the outcomes of human iPSC-derived dopaminergic neuron transplantation into the animal striatum. Neurotransplantation in the main group of animals (n=8) resulted in significant improvement in the motor functions and a reduction of the Parkinsonism symptoms, while similar transplantation of fibroblasts into the animal striatum in the control group (n=4) had no effect on the Parkinsonism symptoms. Immunomorphological analysis demonstrated that differentiated human neurons, which were transplanted into the rat brain, retain their localization in the striatum and remain viable for up to four months after surgery. In this case, the outgrowth of their processes around the transplantation site was observed. The study has demonstrated the fundamental possibility for movement disorders in experimental animals with a 6-OHDA-model of Parkinsonism due to the repopulation of dopaminergic neurons, the source of which may be iPSCs derived from somatic cells (fibroblasts).

About the authors

A. V. Stavrovskaya

Scientific Center of Neurology (Moscow)

Author for correspondence.
Email: platonova@neurology.ru
Russian Federation

D. N. Voronkov

Scientific Center of Neurology (Moscow)

Email: platonova@neurology.ru
Russian Federation

N. G. Yamshchikova

Scientific Center of Neurology (Moscow)

Email: platonova@neurology.ru
) Russian Federation

A. S. Ol’shanskiy

Scientific Center of Neurology (Moscow)

Email: platonova@neurology.ru
Russian Federation

R. M. Khudoerkov

Scientific Center of Neurology (Moscow)

Email: platonova@neurology.ru
Russian Federation

L. G. Khaspekov

Scientific Center of Neurology (Moscow)

Email: platonova@neurology.ru
Russian Federation

S. N. Illarioshkin

Scientific Center of Neurology (Moscow)

Email: platonova@neurology.ru
Russian Federation

References

  1. Иллариошкин С.Н., Загоровская И.А., Иванова-Смоленская И.А.,Маркова Е.Д. Генетические аспекты болезни Паркинсона. Неврол. журнал 2002; 5: 47–51.
  2. Лебедева О.С., Лагарькова М.А., Иллариошкин С.Н. и др. Индуцированные плюрипотентные стволовые клетки: новые возможности в нейробиологии и нейротрансплантологии. Анн. клин. и эксперим. неврол. 2011; 4: 37–45.
  3. Лебедева О.С., Лагарькова М.А., Киселев С.Л. и др. Морфофункциональные свойства индуцированных плюрипотентных стволовых клеток, полученных из фибробластов кожи человека и дифференцированных в дофаминергические нейроны. Нейрохимия 2013; 3: 233–241.
  4. Экстрапирамидные расстройства. Руководство по диагностике и лечению (под ред. В.Н. Штока, И.А. Ивановой-Смоленской, О.С. Левина). М.: МЕДпресс-информ, 2002.
  5. Airavaara M., Voutilalainen M.H., Wang Y., Hoffer B. Neurorestoration. Parkinsonism Relat. Disord. 2012; 18 (Suppl. 1): S143–S146.
  6. Bjorklund A., Kordower J.H. Cell therapy for Parkinson’s disease: what next? Mov. Disord. 2013; 28: 110–115.
  7. Connolly B., Lang A.E. Pharmacological treatment of Parkinson’s disease: a review. JAMA 2014; 311: 1670–1683.
  8. Cooper O., Hallett P., Isacson O. Using stem cells and iPS cells to discover new treatments for Parkinson’s disease. Parkinsonism Relat. Disord. 2012; 18 (Suppl. 1): S14–S16.
  9. Gao A., Peng Y., Deng Y., Qing H. Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases. Neuroscience 2013; 228: 47–59.
  10. Hwang D.-Y., Kim D.S., Kim D.W. Human ES and iPS cells as cell sources for the treatment of Parkinson’s disease: current state and problems. J. Cell. Biochem. 2010; 109: 292–301.
  11. Jenner P., Morris H.R., Robbins T.W. et al. Parkinson’s disease – the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J. Parkinson’s Dis. 2013; 3: 1–11.
  12. Kalia L.V., Lang A.E. Parkinson’s disease. Lancet 2015: published online April 20. http://dx.doi.org/10.1016/S0140-6736(14)61393-3
  13. Korecka JA, Verhaagen J, Hol EM: Cell-replacement and genetherapy strategies for Parkinson’s and Alzheimer’s disease. Regenerative Medicine 2007, 2: 425–446.
  14. Langston J.W. The promise of stem cells in Parkinson’s disease. J. Clin. Invest. 2005; 115: 23–25.
  15. Lindvall O. Developing dopaminergic cell therapy for Parkinson’s disease – give up or move forward? Mov. Disord. 2013; 28: 268–273.
  16. Lindvall O., Kokaia Z., Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders – how to make it work. Nat. Med. 2004; 10 (Suppl.): S42–S50.
  17. Meredith G.E., Sonsalla P., Chesselet M.P. Animal models of Parkinson’s disease progression. Acta Neuropathol. 2008; 115: 385–398.
  18. Nishimura K., Takahashi J. Therapeutic application of stem cell technology toward the treatment of Parkinson’s disease. Biol. Pharm. Bull. 2013; 36: 171–175.
  19. Park I.H., Zhao R., West J.A. et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451 (7175): 141–146.
  20. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, 1998.
  21. Periquet M., Lücking C.B., Vaughan J.R. et al. et al. Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent
  22. recurrent events, whereas point mutations may result from founder effects. Am. J. Hum. Genet. 2001; 68: 617–626.
  23. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006; 116 (7): 1744–1754.
  24. Takahashi K., Tanabe K., Ohnuki M. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131: 861–872.
  25. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663–676.

Statistics

Views

Abstract: 782

PDF (Russian): 550

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) 2017 Stavrovskaya A.V., Voronkov D.N., Yamshchikova N.G., Ol’shanskiy A.S., Khudoerkov R.M., Khaspekov L.G., Illarioshkin S.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies